Voyager Therapeutics, Inc. — Earnings Quality Grade C
VYGR · Healthcare
Some red flags
Screening Summary
Management Signals
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO 16 days, change +9 days YoY
AR growth 17.1% exceeds revenue growth -49.5%
Revenue -49.5%, CFFO -765.2%. Cash follows revenue
Expense Quality
No material inventory
CapEx growth -26.3% vs revenue -49.5%. Normal
Insufficient data
Insufficient data
Cash Flow Quality
CFFO/NI = 1.11. Profits backed by cash
FCF is negative ($-0.1B)
Accruals ratio = 5.1%. Elevated
Cash $0.2B covers debt $0.0B
Balance Sheet Health
No goodwill. Clean balance sheet
Debt/EBITDA = -0.3x. Healthy
Other assets -4.8% vs revenue -49.5%. Normal
No write-off data
Acquisition Risk
FCF after acquisitions negative for 2/3 years
No goodwill
Manipulation Score
Insufficient data
Portfolio monitoring
Monitor VYGR continuously
The full checks and model details are free to read. Use Watchlist to track your holdings; Pro adds automatic quarterly rescoring, risk-event email alerts, scans up to 50 tickers, and export workflows.
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25